HIV Prevention Methods

The Latest

Ending the HIV Epidemic Will Take More Than Medicine

Our HIV research agenda has to address the world outside of a clinical trial, vaccine researcher Stephaun E. Wallace, Ph.D., argues.

By Stephaun E. Wallace, Ph.D.

Making Trans Women Count in HIV Vaccine Trials

"For us who focus on HIV prevention research, it is paramount that we go where the epidemic is in this country," said Michele Andrasik, Ph.D.

By Stephen Hicks

Despite Uptick, Black and Latinx People Have Relatively Low Participation in HIV Vaccine Trials

HIV vaccine researchers are working to study and solve the problem, with a focus on how researchers themselves can more deeply build and earn trust.

By Stephen Hicks

New Campaign, Toolkit Gets Providers PrEP'd for Women

New York City aims to expand PrEP and PEP access by educating more clinicians that serve women.

By Kenyon Farrow

New Website Helps People Trying to Navigate Their PrEP Options

A team led by Shannon Weber, M.S.W., has developed PleasePrEPMe, an online PrEP provider search and chat service.

By Terri Wilder, M.S.W.

Are Urgent Care Centers Prescribing PrEP? Researchers Explore the Answer

A new CDC study suggests that many urgent care centers in the U.S. still need to be made aware of pre-exposure prophylaxis and how to provide it.

By Terri Wilder, M.S.W.

Plan to End HIV Epidemic in U.S. Must Contend With Uneven State Health Care Systems

Best practices need to be replicated, but our health care structure will make doing so more challenging, says Ace Robinson of the Fast-Track Cities initiative.

By Terri Wilder, M.S.W.

Primary Care Providers Aware of PrEP in NYC Suburbs, but Report Barriers to Prescribing

Anthony J. Santella, Dr.P.H., explains why prevention efforts are lagging within the largest suburban HIV epidemic in the U.S.

By Terri Wilder, M.S.W.

Why Do Study Participants Misreport Their HIV Status?

A new study demonstrates the phenomenon, but experts say more research needs to determine why it occurs -- and what researchers can do differently to reduce it.

By Barbara Jungwirth

This Week in HIV Research: From PrEP to Treatment, There's Always More to Learn

April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.

By Barbara Jungwirth and Myles Helfand